Loading...
XHKG1521
Market cap448mUSD
Dec 27, Last price  
1.71HKD
1D
0.59%
1Q
128.00%
IPO
-48.02%
Name

Frontage Holdings Corp

Chart & Performance

D1W1MN
XHKG:1521 chart
P/E
41.47
P/S
1.72
EPS
0.01
Div Yield, %
0.00%
Shrs. gr., 5y
0.61%
Rev. gr., 5y
25.61%
Revenues
260m
+3.79%
48,644,00070,245,00083,114,000100,415,000125,811,000184,441,000250,360,000259,855,000
Net income
11m
-58.00%
6,646,00010,165,00011,241,00018,424,00017,150,00018,428,00025,735,00010,808,000
CFO
40m
-36.36%
9,345,0006,759,00022,658,00018,728,00031,654,00044,549,00062,442,00039,740,000
Earnings
Mar 26, 2025

Profile

Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services that include study designs, execution of studies, and interpretation of the data through structural optimization in early discovery, pharmacokinetic studies in rodents, non- GLP bioanalytical studies, etc. The company also provides safety and toxicology services comprising in-vitro and in-vivo studies; bioequivalence services, which consist of designing, coordinating, and reporting of bioequivalence studies; chemistry services comprising contract research and custom synthesis services; and clinical services, such as early stage clinical, BE/BA, biometric, and data management services. It operates in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
IPO date
May 30, 2019
Employees
1,613
Domiciled in
US
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
259,855
3.79%
250,360
35.74%
184,441
46.60%
Cost of revenue
240,228
216,206
158,364
Unusual Expense (Income)
NOPBT
19,627
34,154
26,077
NOPBT Margin
7.55%
13.64%
14.14%
Operating Taxes
3,849
10,196
6,144
Tax Rate
19.61%
29.85%
23.56%
NOPAT
15,778
23,958
19,933
Net income
10,808
-58.00%
25,735
39.65%
18,428
7.45%
Dividends
Dividend yield
Proceeds from repurchase of equity
(2,890)
(7,190)
2,252
BB yield
0.06%
0.12%
-0.03%
Debt
Debt current
31,809
24,243
7,300
Long-term debt
176,949
104,461
108,389
Deferred revenue
2,061
2,123
Other long-term liabilities
(12,982)
18,018
Net debt
144,043
29,454
(39,928)
Cash flow
Cash from operating activities
39,740
62,442
44,549
CAPEX
(21,137)
(47,665)
(50,380)
Cash from investing activities
(87,626)
(147,910)
(107,443)
Cash from financing activities
12,910
30,659
(5,544)
FCF
2,255
(20,433)
(42,803)
Balance
Cash
54,598
90,520
148,707
Long term investments
10,117
8,730
6,910
Excess cash
51,722
86,732
146,395
Stockholders' equity
119,457
111,339
95,932
Invested Capital
440,583
378,334
298,197
ROIC
3.85%
7.08%
7.00%
ROCE
3.89%
7.18%
6.43%
EV
Common stock shares outstanding
2,069,710
2,084,432
2,115,688
Price
2.32
-20.00%
2.90
-26.58%
3.95
-6.40%
Market cap
4,801,728
-20.57%
6,044,853
-27.67%
8,356,966
-4.73%
EV
4,948,415
6,077,076
8,320,280
EBITDA
55,201
63,593
49,569
EV/EBITDA
89.64
95.56
167.85
Interest
7,072
3,948
2,579
Interest/NOPBT
36.03%
11.56%
9.89%